Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme.
Bottom Line: Coadministration did not change the overall safety profile.No new safety signals were identified.The data confirm previous findings that HPV-16/18-vaccine has an acceptable benefit-risk profile in adolescent girls and adult women.
Affiliation: GlaxoSmithKline Vaccines, Wavre, Belgium.Show MeSH
Related in: MedlinePlus
Mentions: Symptoms were reported within 30 days after each dose by 30.8% (95%CI 30.2–31.3) of subjects in the HPV group, 29.7% (29.1–30.3) of controls and 48.1% (45.9–50.2) in the Coad group (Figure 2). The most frequently reported Preferred Terms in each group were upper respiratory tract infection, nasopharyngitis and headache.